tradingkey.logo
tradingkey.logo
Search

TriSalus Life Sciences Inc

TLSI
Add to Watchlist
4.160USD
+0.130+3.23%
Close 06/24, 16:00ETQuotes delayed by 15 min
255.48MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-24
Previous score
8.00
Change
0
The current earnings forecast score of TriSalus Life Sciences Inc is 8.00, ranking 167 out of 388 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 9.00.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
8.800
Target Price
+115.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

561
Total
5
Median
6
Average
Company name
Ratings
Analysts
TriSalus Life Sciences Inc
TLSI
5
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is TriSalus Life Sciences Inc's expected revenue for the next quarter?

TriSalus Life Sciences Inc's expected revenue is 10.27M.

What is TriSalus Life Sciences Inc's price target?

Analysts forecast that TriSalus Life Sciences Inc's price target is USD 11.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 9.00.

How have TriSalus Life Sciences IncTLSI's recent earnings per share performed?

The market expectation was USD 0.03, while TriSalus Life Sciences IncTLSI's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.15.

What is the analyst rating for TriSalus Life Sciences Inc?

Based on the ratings of TriSalus Life Sciences Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI